Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sarina Agkatsev"'
Autor:
Franziska Maria Ippen, Angelika Scherm, Tobias Kessler, Peter Hau, Sarina Agkatsev, Hansjörg Baurecht, Wolfgang Wick, Helge Knüttel, Michael F. Leitzmann, Corinna Seliger‐Behme
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Glioblastoma (GB) is the most common malignant primary brain tumor in adults and is associated with a poor prognosis. Current treatment guidelines outline the standard of care for patients with newly diagnosed GB; however, there i
Externí odkaz:
https://doaj.org/article/007ab5d0000c42e8bd4284bd7935d960
Autor:
Lazaros, Lazaridis, Elisabeth, Bumes, Dorothee, Cäcilia Spille, Tim, Schulz, Sina, Heider, Sarina, Agkatsev, Teresa, Schmidt, Tobias, Blau, Christoph, Oster, Jonas, Feldheim, Walter, Stummer, Almuth Friederike, Kessler, Clemens, Seidel, Oliver, Grauer, Peter, Hau, Ulrich, Sure, Kathy, Keyvani, Ulrich, Herrlinger, Christoph, Kleinschnitz, Martin, Stuschke, Ken, Herrmann, Cornelius, Deuschl, Stella, Breuer, Elke, Hattingen, Björn, Scheffler, Sied, Kebir, Martin, Glas
Publikováno v:
Neuro-oncology advances. 4(1)
The randomized phase 3 CeTeG/NOA-09 trial assessed whether CCNU plus temozolomide was superior to temozolomide alone in newly diagnosedWe retrospectively collected clinical and radiographic data from adult newly diagnosedSeventy patients were include
Autor:
Teresa Schmidt, Sarina Agkatsev, Jonas Feldheim, Christoph Oster, Tobias Blau, Ulrich Sure, Kathy Keyvani, Christoph Kleinschnitz, Martin Stuschke, Ken Hermann, Cornelius Deuschl, Björn Scheffler, Sied Kebir, Martin Glas, Lazaros Lazaridis
Publikováno v:
Neuro-Oncology. 24:vii81-vii82
Disease relapse almost inevitably occurs in patients with adult-type diffuse glioma. Standard of care treatment options at tumor relapse are still not well defined. Few studies indicate that the combination of trofosfamide plus etoposide (T/E) may be
Autor:
Sied Kebir, Lazaros Lazaridis, Wolfgang Wick, Michael Platten, Ghazaleh Tabatabai, Stephanie E Combs, Teresa Schmidt, Sarina Agkatsev, Tobias Blau, Irina Mäurer, Ulf Kahlert, Andre Sagerer, Anne Berberich, Sina Heider, Michael Müther, Raphael Bodensohn, Felix Behling
Publikováno v:
Neuro Oncol
Neuro. Oncol. 24, 1609-1611 (2022)
Web of Science
Neuro. Oncol. 24, 1609-1611 (2022)
Web of Science
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d54a11b0939a69bbd742f4a85b6c81a2
https://europepmc.org/articles/PMC9435481/
https://europepmc.org/articles/PMC9435481/
Autor:
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, Tim Schulz, Sina Heider, Sarina Agkatsev, Teresa Schmidt, Tobias Blau, Christoph Oster, Jonas Feldheim, Walter Stummer, Almuth Friederike Kessler, Clemens Seidel, Oliver Grauer, Peter Hau, Ulrich Sure, Kathy Keyvani, Ulrich Herrlinger, Christoph Kleinschnitz, Martin Stuschke, Ken Herrmann, Cornelius Deuschl, Stella Breuer, Elke Hattingen, Björn Scheffler, Sied Kebir, Martin Glas
Background The randomized phase 3 CeTeG/NOA-09 trial assessed whether CCNU plus temozolomide was superior to temozolomide alone in newly diagnosed MGMT promoter methylated glioblastoma patients. Survival was significantly improved from 31.4 months (t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea762efd4533c8c29299267f5edd51fc
https://www.ncbi.nlm.nih.gov/pubmed/36284931
https://www.ncbi.nlm.nih.gov/pubmed/36284931
Autor:
Lazaros Lazaridis, Teresa Schmidt, Sarina Agkatsev, Clemens Seidel, Tim Schulz, Almuth F. Kessler, Elisabeth Bumes, Peter Hau, Dorothee Spille, Walter Stummer, Christoph Kleinschnitz, Bjoern Scheffler, Sied Kebir, Martin Glas
Publikováno v:
WFNOS 2022 Abstract Book.
Autor:
Sied Kebir, Lazaros Lazaridis, Wolfgang Wick, Michael Platten, Ghazaleh Tabatabai, Stephanie Combs, Teresa Schmidt, Sarina Agkatsev, Tobias Blau, Irina Mäurer, Ulf Kahlert, Andre Sagerer, Anne Berberich, Sina Heider, Michael Müther, Raphael Bodensohn, Felix Behling
Publikováno v:
Neuro-Oncology. 24:vii129-vii129
PURPOSE Satisfaction with work-life balance (WLB) is an essential factor for persistent motivation of early career researchers. However, WLB satisfaction in the neuro-oncological landscape is not well characterized. We present the results of an inter
Autor:
Lazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, Tim Schulz, Sina Heider, Sarina Agkatsev, Teresa Schmidt, Tobias Blau, Christoph Oster, Jonas Feldheim, Walter Stummer, Almuth Friederike Kessler, Clemens Seidel, Oliver Grauer, Peter Hau, Ulrich Sure, Kathy Keyvani, Ulrich Herrlinger, Christoph Kleinschnitz, Martin Stuschke, Ken Herrmann, Cornelius Deuschl, Stella Breuer, Elke Hattingen, Björn Scheffler, Sied Kebir, Martin Glas
Publikováno v:
Neuro-Oncology. 24:vii74-vii74
BACKGROUND The randomized phase 3 CeTeG/NOA-09 trial assessed whether CCNU plus temozolomide was superior to temozolomide alone in newly diagnosed MGMT promoter methylated glioblastoma patients. Survival was significantly improved from 31.4 months (t